Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Terence Marques Williams

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1020-0845; OpenAlex author ID A5040079785, A5139108350; NIH RePORTER profile ID 10505185. Sources: OpenAlex.

Their work

Papers
31 (first author 1, last author 13)
Trials
0
Grants
1
Labs led
4
Collaborators
133
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 6 papers · 2021: 6 papers, 1 grant · 2022: 3 papers · 2023: none · 2024: 3 papers · 2025: 2 papers · 2026: 2 papers

Papers 31

  1. High SMAD4 Expression is Associated With Improved Clinical Outcomes in Patients With Resectable Pancreatic Cancer: An Analysis of NRG Oncology/RTOG 9704. Co-author DOI 10.1016/j.ijrobp.2026.09.014↗
  2. NEIL2 regulates RNA polymerase II dynamics to suppress transcription–replication conflicts in pancreatic cancer Co-author DOI 10.64898/2026.10.19.760262↗
  3. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  4. KRAS-induced STN1 (OBFC1) promotes proper CTC1-STN1-TEN1 complex-independent DNA double-strand break repair and cell cycle checkpoint maintenance in pancreatic… Last author DOI 10.1093/nar/gkaf983↗
  5. Base-excision repair pathway regulates transcription-replication conflicts in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2024.114820↗
  6. SBRT for Pancreatic Cancer: A Radiosurgery Society Case-Based Practical Guidelines to Challenging Cases. Co-author DOI 10.1016/j.prro.2024.06.004↗
  7. Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions. Last author DOI 10.1126/sciadv.adj3551↗
  8. Identification of circulating plasma ceramides as a potential sexually dimorphic biomarker of pancreatic cancer-induced cachexia. Co-author DOI 10.1002/rco2.68↗
  9. First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population. Co-author DOI 10.2217/fon-2021-1367↗
  10. Advances in Radiation Oncology for Pancreatic Cancer: An Updated Review. Last author DOI 10.3390/cancers14235725↗
  11. Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems. Co-author DOI 10.1016/j.humpath.2020.11.010↗
  12. Increasing neutrophil-to-lymphocyte ratio following radiation is a poor prognostic factor and directly correlates with splenic radiation dose in pancreatic can… Last author DOI 10.1016/j.radonc.2021.02.035↗
  13. Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic… Last author DOI 10.1158/1078-0432.ccr-20-1422↗
  14. Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-4781↗
  15. EMT-Induced Gemcitabine Resistance in Pancreatic Cancer Involves the Functional Loss of Equilibrative Nucleoside Transporter 1. Co-author DOI 10.1158/1535-7163.mct-20-0316↗
  16. Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers13205168↗
  17. Recurrence After Resection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2019.5464↗
  18. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgic… Last author DOI 10.1002/cam4.3075↗
  19. Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes. Co-author DOI 10.1016/j.hpb.2020.01.013↗
  20. A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection. Last author DOI 10.18632/oncotarget.27496↗
  21. Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study. Co-author DOI 10.3390/cancers12123656↗
  22. Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. Co-author DOI 10.3390/jcm9041129↗
  23. Radiation-Induced Colitis in a Pancreatic Cancer Patient With a Germline BRCA2 Mutation: A Case Report. Last author DOI 10.1016/j.adro.2018.08.025↗
  24. Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemo… Last author DOI 10.1097/coc.0000000000000452↗
  25. Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence. First author DOI 10.21037/apc.2018.08.02↗
  26. Prognostic value of microRNA expression levels in pancreatic adenocarcinoma: a review of the literature. Last author DOI 10.18632/oncotarget.20277↗
  27. Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. Last author DOI 10.1038/srep10867↗
  28. MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways. Last author DOI 10.1080/15384101.2015.1104437↗
  29. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Co-author DOI 10.1002/cncr.28117↗
  30. Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Co-author DOI 10.1158/1535-7163.mct-12-0098↗
  31. Role of α(5)β(1) Integrin Up-regulation in Radiation-Induced Invasion by Human Pancreatic Cancer Cells. Co-author DOI 10.1593/tlo.11133↗

Grants 1

  1. Exploiting Caveolae-Dependent Albumin Endocytosis to optimize Therapy in Pancreatic Cancer R01CA198128↗

Closest collaborators

The 25 strongest of 133 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Adam R. Wolfe · 9 shared papers, 2018–2024 · strength 1.18
  2. Mary E. Dillhoff · 9 shared papers, 2017–2022 · strength 0.97
  3. Ryan N. Robb · 5 shared papers, 2020–2026 · strength 0.73
  4. Jordan M. Cloyd · 6 shared papers, 2020–2025 · strength 0.71
  5. Laith I. Abushahin · 5 shared papers, 2020–2022 · strength 0.61
  6. Mustafa Raoof · 3 shared papers, 2022–2026 · strength 0.58
  7. Karyn A. Goodman · 3 shared papers, 2020–2025 · strength 0.52
  8. Allan Tsung · 4 shared papers, 2020–2021 · strength 0.46
  9. Wei Chen · 4 shared papers, 2020–2021 · strength 0.44
  10. Fan Meng · 2 shared papers, 2024–2026 · strength 0.43
  11. Marc A. Attiyeh · 2 shared papers, 2024–2026 · strength 0.43
  12. Timothy Michael Pawlik · 4 shared papers, 2018–2020 · strength 0.43
  13. Wendy L. Frankel · 3 shared papers, 2020–2021 · strength 0.37
  14. Joanna M. Karasinska · 2 shared papers, 2024–2025 · strength 0.37
  15. James Thomas Topham · 2 shared papers, 2024–2025 · strength 0.37
  16. David F. Schaeffer · 2 shared papers, 2024–2025 · strength 0.37
  17. Daniel John Renouf · 2 shared papers, 2024–2025 · strength 0.37
  18. Eugene Jon Koay · 3 shared papers, 2020–2025 · strength 0.35
  19. Aslam M. Ejaz · 3 shared papers, 2020–2021 · strength 0.35
  20. Wei Chen · 2 shared papers, 2021–2024 · strength 0.34
  21. William Adrian Hall · 2 shared papers, 2024–2025 · strength 0.33
  22. Edgar Ben‐Josef · 4 shared papers, 2011–2026 · strength 0.33
  23. Jason Liu · 2 shared papers, 2022–2024 · strength 0.33
  24. Percy P. Lee · 2 shared papers, 2022–2024 · strength 0.33
  25. Anne M. Noonan · 3 shared papers, 2020–2021 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.